## WE CLAIM:

- 1. A personal care absorbent article comprising:
- an outer cover layer;
- a liner layer; and
- a containment layer between the outer cover layer and the liner layer, wherein at least one of the layers is treated with a density modulator.
- 2. The absorbent article of Claim 1, wherein the density modulator is applied to the liner layer.
- 3. The absorbent article of Claim 2, wherein the density modulator is applied to the liner layer in a concentration of up to about 20% by weight of the liner layer.
- 4. The absorbent article of Claim 2, wherein the density modulator is applied to the liner layer in a concentration of between about 5% and about 15% by weight of the liner layer.
- 5. The absorbent article of Claim 2, wherein the density modulator is applied to the liner layer in a concentration of between about 8% and about 12% by weight of the liner layer.

24 MR/S

- 6. The absorbent article of Claim 1, wherein the density modulator is applied to the containment layer.
- 7. The absorbent article of Claim 6, wherein the density modulator is applied to the containment layer in a concentration of up to about 6% by weight of the containment layer.
- 8. The absorbent article of Claim 6, wherein the density modulator is applied to the containment layer in a concentration of between about 0.1% and about 3% by weight of the containment layer.
- 9. The absorbent article of Claim 6, wherein the density modulator is applied to the containment layer in a concentration of between about 0.2% and about 1.5% by weight of the containment layer.
- 10. The absorbent article of Claim 1, wherein the density modulator is applied to both the liner layer and the containment layer.

KCC-1034-CIP1 25 MR/S

- 11. The absorbent article of Claim 1, wherein the density modulator reduces the density of the containment layer without lysing red blood cells when the containment layer comes into contact with a blood-containing bodily fluid.
- 12. The absorbent article of Claim 1, wherein the at least one layer treated with the density modulator increases in thickness by at least about 12% when the at least one layer comes into contact with a blood-containing bodily fluid.
- 13. The absorbent article of Claim 1, wherein the at least one layer treated with the density modulator is a nonwoven web material selected from the group consisting of airlaid, airformed, wetlaid, absorbent laminates, nonwovens, fluid permeable polymeric film, and combinations thereof.
- 14. The absorbent article of Claim 13, wherein the at least one layer treated with the density modulator comprises at least one superabsorbent dispersed throughout the nonwoven web material.
- 15. The absorbent article of Claim 1, wherein the density modulator comprises alkyl glycoside.

KCC-1034-CIP1 26 MR/S

- 16. A wound dressing comprising the absorbent article of Claim
  1.
  - 17. A catamenial device comprising:

an outer cover layer;

- a liner layer; and
- a containment layer between the outer cover layer and the liner layer, wherein at least one of the layers is treated with a density modulator.
- 18. The catamenial device of Claim 17, wherein the density modulator is applied to the liner layer.
- 19. The catamenial device of Claim 18, wherein the density modulator is applied to the liner layer in a concentration of up to about 20% by weight of the liner layer.
- 20. The catamenial device of Claim 18, wherein the density modulator is applied to the liner layer in a concentration of between about 5% and about 15% by weight of the liner layer.

KCC-1034-CIP1 27 MR/S

- 21. The catamenial device of Claim 18, wherein the density modulator is applied to the liner layer in a concentration of between about 8% and about 12% by weight of the liner layer.
- 22. The catamenial device of Claim 17, wherein the density modulator is applied to the containment layer.
- 23. The catamenial device of Claim 22, wherein the density modulator is applied to the containment layer in a concentration of up to about 6% by weight of the liner layer.
- 24. The catamenial device of Claim 22, wherein the density modulator is applied to the containment layer in a concentration of between about 0.1% and about 3% by weight of the liner layer.
- 25. The catamenial device of Claim 22, wherein the density modulator is applied to the containment layer in a concentration of between about 0.2% and about 1.5% by weight of the liner layer.
- 26. The catamenial device of Claim 17, wherein the density modulator is applied to both the liner layer and the containment layer.

KCC-1034-CIP1 28 MR/S

- 27. The catamenial device of Claim 17, wherein the density modulator reduces the density of the containment layer without lysing red blood cells when the containment layer comes into contact with a blood-containing bodily fluid.
- 28. The catamenial device of Claim 17, wherein the at least one layer treated with the density modulator increases in thickness by at least about 12% when the at least one layer comes into contact with a blood-containing bodily fluid.
- 29. The catamenial device of Claim 17, wherein the at least one layer treated with the density modulator is a nonwoven web material selected from the group consisting of airlaid, airformed, wetlaid, absorbent laminates, nonwovens, fluid permeable polymeric film, and combinations thereof.
- 30. The catamenial device of Claim 29, wherein the at least one layer treated with the density modulator comprises at least one superabsorbent dispersed throughout the nonwoven web material.

KCC-1034-CIP1 29 MR/S

- 31. The catamenial device of Claim 17, wherein the density modulator comprises alkyl glycoside.
  - 32. A catamenial device comprising: a porous synthetic substrate treated with alkyl glycoside.
- 33. The catamenial device of Claim 32, wherein the alkyl glycoside is applied to the substrate in a concentration of between about 0.1% and about 8% by weight of the treated substrate.
- 34. The catamenial device of Claim 32, wherein the alkyl glycoside is applied to the substrate in a concentration of between about 0.25% and about 3% by weight of the treated substrate.
- 35. The catamenial device of Claim 32, wherein the alkyl glycoside is applied to the substrate in a concentration of between about 0.3% and about 1.5% by weight of the treated substrate.
- 36. The catamenial device of Claim 32, wherein the alkyl glycoside reduces the density of the substrate without lysing red blood cells when the substrate comes into contact with a blood-containing bodily fluid.

KCC-1034-CIP1 30 MR/S

- 37. The catamenial device of Claim 32, wherein the substrate treated with the alkyl glycoside increases in thickness by at least about 12% when the substrate comes into contact with a blood-containing bodily fluid.
- 38. The catamenial device of Claim 32, wherein the substrate is a nonwoven web material selected from the group consisting of airlaid, airformed, wetlaid, absorbent laminates, nonwovens, fluid permeable polymeric film, and combinations thereof.
- 39. The catamenial device of Claim 38, wherein the substrate comprises at least one superabsorbent dispersed throughout the nonwoven web material.
  - 40. A sanitary pad comprising the catamenial device of Claim 32.
  - 41. A tampon comprising the catamenial device of Claim 32.

KCC-1034-CIP1 31 MR/S